Piroxicam Pharmacokinetics in Man: Aspirin and Antacid Interaction Studies

Hobbs, Donald C.; Twomey, Thomas M.

doi:10.1002/j.1552-4604.1979.tb02480.x

Cited by 103 publications

(30 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The half-life of piroxicam has been found to range between 14.1 and 158.3 h in normal young men (Hobbs & Twomey, 1979). The mean half-life for our group of mainly elderly patients is longer than those described for younger subjects in the This is also observed for other drugs, e.g.…”

Section: Discussionsupporting

confidence: 49%

Pharmacokinetic observations on piroxicam in young adult, middle‐aged and elderly patients.

Woolf¹,

Rogers²,

Bradbrook³

et al. 1983

Brit J Clinical Pharma

View full text Add to dashboard Cite

Nineteen out of 21 patients with painful conditions of the locomotor system aged between 27 and 94 years completed a study in which they received 20 mg piroxicam daily for 14 days. Plasma piroxicam concentrations were estimated by high performance liquid chromatography. Pharmacokinetic analysis of the data showed the half-life and systemic clearance of piroxicam to be unaffected by age. The apparent volume of distribution in older patients was higher than that of younger subjects. Multiple regression analysis showed that creatinine clearance and plasma albumin concentration had insignificant effects on the systemic piroxicam clearance. Although improvement in joint pain and stiffness occurred during the 2 week study period, this could not be correlated with plasma piroxicam concentration.

show abstract

Section: Discussionsupporting

confidence: 49%

Pharmacokinetic observations on piroxicam in young adult, middle‐aged and elderly patients.

Woolf¹,

Rogers²,

Bradbrook³

et al. 1983

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…For most sub jects, however, the level of piroxicam was below the level of detection of the HPLC method (19.2ng/ml). In contrast, the mean steady-state levels of piroxicam after oral dos ing in normal subjects is 4.5 pg ml-1 [10]. The results of the study reported here supports the view that treatment with topical piroxicam gel, as an alternative to oral NSAID therapy, is likely to reduce the incidence of adverse events associated with higher systemic levels of drug after oral dosing.…”

Section: Discussionsupporting

confidence: 65%

Plasma and Cutaneous Drug Levels after Topical Application of Piroxicam Gel: A Study in Healthy Volunteers

Marks¹,

Dykes²

1994

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Two studies in healthy male and female volunteers (aged 18–65 years) were undertaken to determine plasma and cutaneous levels of drug following topical application of piroxicam gel. Twelve subjects applied piroxicam gel to the knee (1 g of 0.5% Feldene gel) at baseline and then after 6, 12 and 24 h. Plasma was collected after 1,2,4,6,14,24,28 and 48 h and piroxicam content determined by high-pressure liquid chromatogrÄphy (HPLC). For the majority of samples collected, piroxicam levels were below the limit of detection (LOD) of the assay and the maximum recorded plasma level in any subject at any time point was 75.4 ng/ml. A single application of gel was administered to the forearms of four groups each of 6 subjects, and biopsy samples of the stratum corneum (skin surface biopsy, SBB) and epidermis/dermis were taken after 0.5, 1, 2 and 4 h. The levels of piroxicam were again measured in each sample by HPLC. The highest levels of piroxicam were found in the superficial skin surface biopsy with the lowest levels recorded in the skin surface biopsies nearest the viable epidermis. The mean tissue concentrations ranged from 160 to 640 ng per sample (calculated to be 80–320 µg/g of tissue). The mean levels of piroxicam in a 4-mm punch biopsy showed an increase with time after application, rising from 60.3 to 94.6 ng per biopsy (calculated to be 2.4 to 3.8 µg/g of tissue). It may be concluded that piroxicam rapidly permeates through the stratum corneum into the epidermis/dermis after application of the gel. Low and often undetectable plasma levels of drug were observed after topical application of piroxicam gel in a manner comparable to clinical usage.

show abstract

“…Concurrent administration of ASA decreased the plasma protein binding of ketoprofen and increased its plasma clearance at steady state (Williams et al, 1981). However the absorption and disposition of piroxicam was apparently unaffected by concomitant administration of ASA (Hobbs & Twomey, 1979). In contrast aspirin has been reported to markedly reduce the bioavailability of diclofenac as measured by AUC (Fowler, 1979).…”

Section: Discussionmentioning

confidence: 99%

Interaction of isoxicam with acetylsalicylic acid.

Esquivel¹,

Cussenot²,

East³

et al. 1984

Brit J Clinical Pharma

View full text Add to dashboard Cite

Ten healthy male volunteers were given 200 mg p.o. of isoxicam after an overnight fast and the plasma concentrations over time followed for 96 h by h.p.l.c. Five days later enteric coated acetylsalicylic acid (ASA) 650 mg four times daily was started and continued for 10 days producing steady state trough plasma salicylate of 83 mg/l (range 21‐133). A second 200 mg isoxicam dose was given 5 days after starting ASA and the plasma concentration time‐curve again followed. After ASA, there was no change in lag time (0.54 vs 0.51 h), time to peak concentration (10 vs 10 h), or disappearance t1/2 (28.7 vs 31.0 h) however the peak isoxicam concentration and AUC were reduced 18 and 22% respectively (P less than 0.01). Plasma protein binding of isoxicam studied by equilibrium dialysis was 96 +/‐ 1% in the absence and 86 +/‐ 5% in the presence of ASA. The reduction in binding was unrelated to plasma SA concentrations achieved or observed reductions in AUC for plasma isoxicam. ASA decreased plasma isoxicam binding, peak plasma isoxicam concentrations and AUC without altering the apparent disappearance half‐life of total plasma isoxicam after a single oral dose.

show abstract

Piroxicam Pharmacokinetics in Man: Aspirin and Antacid Interaction Studies

Cited by 103 publications

References 21 publications

Pharmacokinetic observations on piroxicam in young adult, middle‐aged and elderly patients.

Pharmacokinetic observations on piroxicam in young adult, middle‐aged and elderly patients.

Plasma and Cutaneous Drug Levels after Topical Application of Piroxicam Gel: A Study in Healthy Volunteers

Interaction of isoxicam with acetylsalicylic acid.

Contact Info

Product

Resources

About